Latest Equities News

Buru Energy advances its Rafael Gas Project with strong funding interest and a $2.35 million capital raise, setting the stage for critical 2026 drilling and resource validation.

Cyprium Metals has secured $80 million in funding and advanced key infrastructure works to restart copper production at its Nifty Copper Complex, targeting first cathode output by mid-2026.

Eagle Mountain Mining has issued nearly 120 million new shares and 40 million options, raising just over $1 million, but a significant shortfall remains to be placed. The company aims to secure additional funding to advance its Arizona copper-gold projects.

Zelira Therapeutics has raised nearly US$33 million from ThirdGate Capital to advance its HOPE® 1 drug targeting autism-related Phelan-McDermid Syndrome through FDA clinical trials. This funding milestone sets the stage for pivotal regulatory progress in the US.

Noble Helium has received a further unsecured loan of AUD 250,000 from its Executive Chair to support working capital, highlighting management’s confidence amid ongoing refinancing efforts.

Orthocell has increased its investment in Marine Biomedical to 11.7%, securing exclusive distribution rights to the innovative PearlBone™ technology as it nears FDA approval.

Noble Helium has restructured its VAT shortfall loan, extending maturity to mid-2027 and raising $2.15 million through a convertible loan note to support its strategic turnaround and Rukwa drilling program.

Mirrabooka Investments reported a 93.6% jump in half-year profit to $8.9 million, maintaining its fully franked dividend despite portfolio returns trailing the small and mid-cap benchmark.

London City Equities reveals a strong half-year performance with an 18% rise in investment portfolio values and a favourable legal development involving Excelsior Capital. The company anticipates increased liquidity and is actively seeking new long-term investments.

Recce Pharmaceuticals has received a $5.3 million R&D tax rebate from the Australian Taxation Office, providing a significant cash injection to support its innovative synthetic anti-infective drug development programs.

Argent BioPharma has signed a binding agreement to acquire AusCann’s 48% stake in CannPal, enhancing its clinical and intellectual property assets for CannEpil®. The deal includes an option for the Neuvis® drug-delivery platform and aligns with Argent’s U.S. dual-listing ambitions.

Ion Video Limited has completed significant restructuring, strengthened its Melbourne-based tech team, and raised $2.95 million, positioning itself for a technology relaunch in February 2026 with a cash runway extending to mid-2027.